NTT
25.7.2022 14:02:12 CEST | Business Wire | Press release
NTT Anode Energy Corporation (President and CEO: Teruyuki Kishimoto, Head Office: Minato-ku, Tokyo, NTT Anode Energy) announced a joint research and development project to study safety measures for the mass transportation of hydrogen through existing pipeline infrastructure. The study, being performed in collaboration with the National Institute of Advanced Industrial Science and Technology (President: Kazuhiko Ishimura, Chiyoda-ku, Tokyo AIST) and Toyota Tsusho Co., Ltd. (Representative Director: Ichiro Kashitani, Minato-ku, Tokyo, Toyota Tsusho), is expected to contribute to the realization of a pipeline transportation model for hydrogen that could be implemented globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005285/en/
According to a paper published by the International Renewable Energy Agency , “Hydrogen has emerged as an important part of the clean energy mix needed to ensure a sustainable future.” However, the large-scale, stable transportation of hydrogen through new pipeline infrastructure faces issues including land acquisition construction costs and building time. Utilizing existing pipeline infrastructure can solve these issues, and this new study represents the next step in this model’s proof-of-concept process.
The study will examine a double-piping system in which a hydrogen pipeline is placed in an existing pipe (the “sheath pipe”) buried underground. Factors to be measured and contributed to the formulation of technical standards include:
- On-site investigation of hydrogen leakage detection
- Verification of detection of signs of abnormality
- Establishment of a control sequence to ensure safety
- Performance evaluation of various hydrogen sensors in a real-world environment
Safety measures will be investigated under the assumption of unsteady conditions including rupture accidents and natural disasters during pipeline operation. In addition to examining the safety measures necessary for such use of existing pipelines, the study will verify the profitability of such projects, including cost analysis of transportation; energy input; and economic efficiency, as compared to other hydrogen transportation means.
Based on the knowledge and data gained through this project, NTT Anode Energy and its collaborators will promote and establish technical studies on safety measures for practical use. Ultimately, the project will also support the future supply of hydrogen to urban areas (e.g., public and commercial facilities, data centers and communications buildings; fuel cell vehicles; hydrogen stations, etc.), supply through pipelines utilizing communication pipelines (e.g., cable tunnels) and will contribute to the development of smart cities and the establishment of hydrogen supply means through pipelines in regions with a view to a society that consumes a large amount of hydrogen through the development of CO2-free hydrogen.
This project is being conducted in accordance with the "Research and development for the full-scale popularization of ultra-high pressure hydrogen infrastructure/Research and development for international development, international standardization, etc./Research and study for the examination of technical standards for hydrogen supply infrastructure, etc." of the New Energy and Industrial Technology Development Organization .
Primary Areas of Research by Collaborator
NTT Anode Energy
- Hydrogen leakage detection;
- Abnormal sign detection;
- Hydrogen sensors investigation;
- Investigation of residual hydrogen concentration at the time of hydrogen leakage; and
- Investigation of explosion effect of manhole cover
AIST
- Investigation of fire flame behavior caused by the ignition of leaked hydrogen in a simulated double piping system
Toyota Tsusho
- Clarification of unit costs through verification of equipment, installation and safety costs; and
- Verification of advantageous conditions and business establishment requirements of pipeline transportation
About NTT Anode Energy Group
As a company focused on leveraging the information communications technology and DC power supply technologies of the NTT Group in pursuit of “smart energy” business opportunities, NTT Anode Energy is working to develop and deliver energy solutions that make more sophisticated and efficient use of distributed energy resources such as renewable power generation facilities and storage batteries. In this way, it can fully express the unique synergies of the NTT Group. Through these efforts, we aim to work with partner companies to create new energy distribution mechanisms to help to revitalize industries and shape a more sustainable society.
NTT and the NTT logo are registered trademarks or trademarks of NIPPON TELEGRAPH AND TELEPHONE CORPORATION and/or its affiliates. All other referenced product names are trademarks of their respective owners. © 2022 NIPPON TELEGRAPH AND TELEPHONE CORPORATION
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005285/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
